Ash Attia Joins MicroMed Cardiovascular as Vice President of Asia-Pacific

Industry Veteran to Bring HeartAssist 5 Left Ventricular Assist Device to Asia Subcontinent, Australia and New Zealand

(PresseBox) ( HOUSTON, )
On Oct. 1, MicroMed Cardiovascular (, manufacturer of the HeartAssist 5(TM) left ventricular assist device (LVAD), announced that Ash Attia has joined the company as Vice President of Asia-Pacific. Attia will be responsible for the launch, management and expansion of the HeartAssist 5 in the region, which includes China, Japan, India, Southeast Asia, Australia and New Zealand.

"Ash has more than 20 years of experience in medical devices and expanding cutting edge technology into the Asia-Pacific region," said Bill Birdsall, MicroMed CEO. "His knowledge and leadership are critical to bringing the HeartAssist 5 to an underserved patient population in need of our life-saving technology."

Attia has held several senior executive roles within the medical devices industry. Most recently, Attia held the position of Vice President of Asia-Pacific for Ventracor Limited, an Australian manufacturer of ventricular assist devices.

Prior to Ventracor, Attia founded Biotronik Australia and subsequently Biotronik Asia Pacific. As Vice President and Managing Director, he expanded business throughout the region in Cardiac Rhythm Management devices, Vascular Interventions and Electrophysiology.

Prior to this, Attia was General Manager of Sulzer International's Cardiovascular division, where he managed a group of companies in the areas of Cardiac Rhythm Management, Vascular devices, Cardiac Surgery and Electrophysiology.

The HeartAssist 5 pump weighs 92 grams and measures 2.8 x 1.2 inches. Because of its miniature size, it is one of the few LVADs that can be implanted above the diaphragm, adjacent to the heart. The HeartAssist 5 is the only LVAD with a precise, direct flow measurement system.

For more information, please visit

In Europe, the HeartAssist 5(TM) , the Modern DeBakey VAD(TM) , has CE Marks for both adult and pediatric use. In the U.S., the HeartAssist 5, formerly DeBakey VAD® Child, is the only FDA-approved pediatric VAD. A bridge-to-transplant IDE clinical study is currently underway in the U.S. for adults.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to